The Ministry of Antimonopoly Regulation and Trade and the Healthcare Ministry are discussing the possibility of expanding the list of drugs that suppliers import to Belarus according to the reference principle. This means that the wholesale price is fixed based on how much the medicine costs in the markets of other countries similar to ours. This year, this approach was applied to oncological and cardiovascular drugs. In some cases, the cost has decreased by almost a half. Ministry of Antimonopoly Regulation and Trade constantly monitors the cost of all medicines in the pharmacy network. In terms of market volume, more than 50% of the drugs are of domestic production. 7 years ago, this figure was only 18%.